What Does NovoLog Cost in 2026?

NovoLog is the brand name for insulin aspart, a rapid-acting insulin analog manufactured by Novo Nordisk. FDA-approved since 2000 (NDA 20-986), NovoLog is indicated to improve glycemic control in adults and children with diabetes mellitus types 1 and 2. Fiasp is a faster-formulation version of insulin aspart, also from Novo Nordisk. Both products are self-injected before meals and begin lowering blood glucose within 10 to 20 minutes. Patients using an insulin pump may also use NovoLog or Fiasp in continuous subcutaneous infusion.

NovoLog and Fiasp are two of the 10 drugs selected for the first round of Medicare price negotiation under the Inflation Reduction Act of 2022. CMS announced a Maximum Fair Price of $119 for a 30-day supply, effective January 1, 2026, representing a 76 percent reduction from the pre-negotiation list price. Medicare Part D also caps insulin patient costs at $35 per month under the IRA insulin cap, so most Medicare patients pay approximately $30 per month for NovoLog. Walmart offers a private-label version called ReliOn NovoLog for $72.88 per vial, manufactured by Novo Nordisk, which is the most affordable option for cash-pay patients without Medicare coverage. Patients with low income who cannot afford insulin should review Medicaid income limits to determine if Medicaid coverage applies.

Two biosimilar alternatives to NovoLog entered the US market in 2025. Merilog (insulin aspart-szjj), made by Sanofi, received FDA approval in February 2025 as the first rapid-acting insulin biosimilar. Kirsty (insulin aspart-xjhz), made by Biocon Biologics, received FDA approval in July 2025 with interchangeable designation, meaning pharmacists can substitute it for NovoLog without a new prescription. Both biosimilars are priced lower than branded NovoLog and are capped at $35 per month for Medicare patients. Patients whose commercial plans or formulary tiers list NovoLog as a brand medication should ask their prescriber about substituting an interchangeable biosimilar to reduce cost. For a comparison of rapid-acting insulin options, see the Humalog cost guide.

What NovoLog Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same novolog can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

NovoLog and other rapid-acting insulins appear on hospital bills at charges that are 5 to 15 times the retail vial price. When a patient requires insulin during an inpatient stay, the hospital pharmacy dispenses individual doses from a multi-dose vial and bills each dose at the facility chargemaster rate. A single 10-unit dose of insulin, which costs under $1.50 at retail rates, can appear on an itemized hospital bill at $50 to $150 or more. The entire cost of a vial used during one hospital stay can be billed at $400 to $1,200 even though the retail price of the same vial is under $300.

Three structural factors drive insulin's hospital markup. First, hospitals set chargemaster rates independent of acquisition cost, typically applying a multiplier of 3 to 10 times what they paid. Second, insulin administration in a clinical setting is billed under HCPCS codes J1815 or J1817 (injection, insulin, per 5 units), and the facility may add nursing administration charges and pharmacy handling fees on top of the drug cost. Third, some hospitals bill an entire new vial per patient even when a fraction of it was used. If you see NovoLog or insulin aspart on an inpatient itemized bill at a unit cost over $50, request a line-by-line breakdown of acquisition cost versus facility fee before paying. The 2026 Medicare Part B ASP for insulin under J1815 is approximately $12 per unit, which provides a useful benchmark for disputing excessive facility charges.

HCPCS J-Codes: What Appears on Your Bill

NovoLog (insulin aspart) administered in a clinical setting is billed under HCPCS Level II J-codes. These codes appear on hospital outpatient claims, physician office infusion bills, and Medicare Part B claims. Self-administered insulin at home is billed under Medicare Part D, not using J-codes.

Patient Assistance Programs

NovoLog's list price without insurance, before using a savings program, ranges from $72.88 per vial at Walmart (ReliOn NovoLog) to about $290 per branded vial at other pharmacies in 2026. Novo Nordisk operates several programs that can reduce or eliminate that cost. Eligibility depends on your insurance status and income. Patients with commercial insurance should use the savings card first. Patients with Medicare or no insurance should apply to the NovoCare Patient Assistance Program.

Medicare Part D Coverage for NovoLog

NovoLog is a Medicare Part D drug. Under the Inflation Reduction Act of 2022, all covered insulins including NovoLog and Fiasp are capped at $35 per month in out-of-pocket cost under Medicare Part D, effective January 1, 2023. That cap applies regardless of your plan's formulary tier, deductible, or coinsurance rate. In 2026, CMS's negotiated Maximum Fair Price of $119 for a 30-day supply of NovoLog means most Medicare patients will pay the lesser of $35 or 25 percent of $119, which is approximately $30. The 2026 annual Part D out-of-pocket cap of $2,000 also applies to all other Part D drugs combined.

Medicare Part D covers NovoLog for type 1 and type 2 diabetes management. Most Part D plans include NovoLog and Fiasp on their formularies, typically at Tier 3 or Tier 4, but the $35 monthly insulin cap overrides the tier-based cost-sharing. Prior authorization is common for NovoLog on many commercial and Medicare Advantage plans. If your plan requires prior authorization, ask your prescriber to submit documentation of your diabetes diagnosis and insulin requirements. Medicare beneficiaries who cannot afford even the $35 monthly cap may qualify for the Extra Help program (Low Income Subsidy), which can reduce cost-sharing to $0 or near $0. Check your eligibility at medicare.gov or call 1-800-MEDICARE.

Patients using an insulin pump who receive NovoLog or Fiasp via continuous subcutaneous infusion may have their insulin covered under Medicare Part B (durable medical equipment benefit) rather than Part D, when the pump itself is covered under Part B. In that scenario, the $35 monthly insulin cap does not apply, but Medicare Part B covers 80 percent of the approved amount after the $283 annual Part B deductible in 2026. Ask your endocrinologist or diabetes educator which benefit covers your pump insulin to avoid billing errors.

Common NovoLog Billing Errors

If you received a bill for NovoLog above $35 per month on Medicare Part D, or above $100 per vial in an outpatient setting, check for these common issues before paying:

• Insulin billed under Part B at J1815 for home self-injection, which should be billed under Part D. Self-administered insulin at home is always Part D. If a clinic submitted a Part B claim for insulin you injected at home, that is a billing error.
• Copay charged above $35 per month for insulin on Medicare Part D. The IRA insulin cap of $35 per month has been effective since January 1, 2023. No Medicare Part D plan may charge more than $35 per month for any covered insulin.
• Prior authorization denial not appealed. If your Part D plan denied NovoLog coverage citing an alternative insulin was required first (step therapy), your prescriber can file a step-therapy exception if medically necessary. Denials are not final until you have exhausted the appeal process.
• Branded NovoLog dispensed when the biosimilar Kirsty (interchangeable designation) was available at lower cost. Ask your pharmacist whether the interchangeable biosimilar substitution was applied at dispensing.
• Hospital bill showing per-dose insulin charges of $50 to $150 per unit when the Medicare ASP under J1815 is approximately $12 per unit. Inpatient facility fees inflate the per-dose cost substantially. Request an itemized bill and compare line items to the J1815 Medicare ASP.

Frequently Asked Questions